Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes

A pooled analysis

Ishwarlal Jialal, Stacey L. Abby, Soamnauth Misir, Sukumar Nagendran

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Colesevelam hydrochloride (COL), a bile acid sequestrant indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia, was shown in a pilot study to reduce both glycated hemoglobin (HbA1c) and LDL-C in patients with type 2 diabetes mellitus (T2DM). Three double-blind, placebo-controlled trials in T2DM have now independently confirmed the HbA1c and LDL-C reductions with COL. In each of the primary studies, a significant mean treatment difference in HbA1c (-0.54%, -0.50%, and -0.54%) and LDL-C (-15.9%, -12.8%, and -16.7%) resulted from the addition of 3.75 grams/day of COL to existing metformin, insulin, or sulfonylurea-based therapy, respectively, in patients with T2DM inadequately controlled on their current antidiabetic regimen. Here we report the results of a pooled analysis of data for the 1018 patients included in the three primary studies. By study end, HbA1c, fasting plasma glucose (FPG), LDL-C, total cholesterol (TC), non-high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein (hsCRP) were significantly reduced with COL versus placebo. Triglyceride (TG) and ApoA-I were significantly increased in the COL group relative to placebo. HDL-C did not change in either group, and the between-group treatment difference was small and not significant. Results of this pooled analysis are consistent with results reported previously in each of the primary COL studies and indicate that the HbA1c and LDL-C-lowering effects of COL are consistent, occurring regardless of whether COL is added to metformin, insulin, or sulfonylurea-based therapy. In conclusion, COL represents a novel therapeutic option by significantly lowering both LDL-C and HbA1c in patients with T2DM, two important treatment goals to forestall vascular complications.

Original languageEnglish (US)
Pages (from-to)255-258
Number of pages4
JournalMetabolic Syndrome and Related Disorders
Volume7
Issue number3
DOIs
StatePublished - Jun 1 2009

Fingerprint

Glycosylated Hemoglobin A
LDL Cholesterol
Type 2 Diabetes Mellitus
Metformin
Placebos
Therapeutics
Insulin
Reducing Diet
Colesevelam Hydrochloride
Apolipoprotein A-I
Apolipoproteins B
Hypercholesterolemia
Bile Acids and Salts
Hypoglycemic Agents
C-Reactive Protein
HDL Cholesterol
Blood Vessels
Fasting
Triglycerides
Cholesterol

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes : A pooled analysis. / Jialal, Ishwarlal; Abby, Stacey L.; Misir, Soamnauth; Nagendran, Sukumar.

In: Metabolic Syndrome and Related Disorders, Vol. 7, No. 3, 01.06.2009, p. 255-258.

Research output: Contribution to journalArticle

@article{473cd1ef536849a695e0a40f706cbad4,
title = "Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: A pooled analysis",
abstract = "Colesevelam hydrochloride (COL), a bile acid sequestrant indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia, was shown in a pilot study to reduce both glycated hemoglobin (HbA1c) and LDL-C in patients with type 2 diabetes mellitus (T2DM). Three double-blind, placebo-controlled trials in T2DM have now independently confirmed the HbA1c and LDL-C reductions with COL. In each of the primary studies, a significant mean treatment difference in HbA1c (-0.54{\%}, -0.50{\%}, and -0.54{\%}) and LDL-C (-15.9{\%}, -12.8{\%}, and -16.7{\%}) resulted from the addition of 3.75 grams/day of COL to existing metformin, insulin, or sulfonylurea-based therapy, respectively, in patients with T2DM inadequately controlled on their current antidiabetic regimen. Here we report the results of a pooled analysis of data for the 1018 patients included in the three primary studies. By study end, HbA1c, fasting plasma glucose (FPG), LDL-C, total cholesterol (TC), non-high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein (hsCRP) were significantly reduced with COL versus placebo. Triglyceride (TG) and ApoA-I were significantly increased in the COL group relative to placebo. HDL-C did not change in either group, and the between-group treatment difference was small and not significant. Results of this pooled analysis are consistent with results reported previously in each of the primary COL studies and indicate that the HbA1c and LDL-C-lowering effects of COL are consistent, occurring regardless of whether COL is added to metformin, insulin, or sulfonylurea-based therapy. In conclusion, COL represents a novel therapeutic option by significantly lowering both LDL-C and HbA1c in patients with T2DM, two important treatment goals to forestall vascular complications.",
author = "Ishwarlal Jialal and Abby, {Stacey L.} and Soamnauth Misir and Sukumar Nagendran",
year = "2009",
month = "6",
day = "1",
doi = "10.1089/met.2009.0007",
language = "English (US)",
volume = "7",
pages = "255--258",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes

T2 - A pooled analysis

AU - Jialal, Ishwarlal

AU - Abby, Stacey L.

AU - Misir, Soamnauth

AU - Nagendran, Sukumar

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Colesevelam hydrochloride (COL), a bile acid sequestrant indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia, was shown in a pilot study to reduce both glycated hemoglobin (HbA1c) and LDL-C in patients with type 2 diabetes mellitus (T2DM). Three double-blind, placebo-controlled trials in T2DM have now independently confirmed the HbA1c and LDL-C reductions with COL. In each of the primary studies, a significant mean treatment difference in HbA1c (-0.54%, -0.50%, and -0.54%) and LDL-C (-15.9%, -12.8%, and -16.7%) resulted from the addition of 3.75 grams/day of COL to existing metformin, insulin, or sulfonylurea-based therapy, respectively, in patients with T2DM inadequately controlled on their current antidiabetic regimen. Here we report the results of a pooled analysis of data for the 1018 patients included in the three primary studies. By study end, HbA1c, fasting plasma glucose (FPG), LDL-C, total cholesterol (TC), non-high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein (hsCRP) were significantly reduced with COL versus placebo. Triglyceride (TG) and ApoA-I were significantly increased in the COL group relative to placebo. HDL-C did not change in either group, and the between-group treatment difference was small and not significant. Results of this pooled analysis are consistent with results reported previously in each of the primary COL studies and indicate that the HbA1c and LDL-C-lowering effects of COL are consistent, occurring regardless of whether COL is added to metformin, insulin, or sulfonylurea-based therapy. In conclusion, COL represents a novel therapeutic option by significantly lowering both LDL-C and HbA1c in patients with T2DM, two important treatment goals to forestall vascular complications.

AB - Colesevelam hydrochloride (COL), a bile acid sequestrant indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia, was shown in a pilot study to reduce both glycated hemoglobin (HbA1c) and LDL-C in patients with type 2 diabetes mellitus (T2DM). Three double-blind, placebo-controlled trials in T2DM have now independently confirmed the HbA1c and LDL-C reductions with COL. In each of the primary studies, a significant mean treatment difference in HbA1c (-0.54%, -0.50%, and -0.54%) and LDL-C (-15.9%, -12.8%, and -16.7%) resulted from the addition of 3.75 grams/day of COL to existing metformin, insulin, or sulfonylurea-based therapy, respectively, in patients with T2DM inadequately controlled on their current antidiabetic regimen. Here we report the results of a pooled analysis of data for the 1018 patients included in the three primary studies. By study end, HbA1c, fasting plasma glucose (FPG), LDL-C, total cholesterol (TC), non-high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein (hsCRP) were significantly reduced with COL versus placebo. Triglyceride (TG) and ApoA-I were significantly increased in the COL group relative to placebo. HDL-C did not change in either group, and the between-group treatment difference was small and not significant. Results of this pooled analysis are consistent with results reported previously in each of the primary COL studies and indicate that the HbA1c and LDL-C-lowering effects of COL are consistent, occurring regardless of whether COL is added to metformin, insulin, or sulfonylurea-based therapy. In conclusion, COL represents a novel therapeutic option by significantly lowering both LDL-C and HbA1c in patients with T2DM, two important treatment goals to forestall vascular complications.

UR - http://www.scopus.com/inward/record.url?scp=66149184527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149184527&partnerID=8YFLogxK

U2 - 10.1089/met.2009.0007

DO - 10.1089/met.2009.0007

M3 - Article

VL - 7

SP - 255

EP - 258

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 3

ER -